Author

Antonett Madriaga

Observed names: Antonett MADRIAGA, Antonett P. Madriaga (7989419)

Observed institution: University of Illinois Chicago

OpenAlex ID: A5078895867

Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis

2015 · Daniel J. Anderson, Ronan Le Moigne, et al. · Cancer Cell · 391

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)

2015 · Han-Jie Zhou, Jinhai Wang, et al. · Journal of Medicinal Chemistry · 199

Structure and Dynamics of Highly PEG-ylated Sterically Stabilized Micelles in Aqueous Media

2011 · Lela Vuković, Fatima A. Khatib, et al. · Journal of the American Chemical Society · 120

CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity

2019 · Victoria A. Assimon, Yangzhong Tang, et al. · ACS Chemical Biology · 96

Solubilization of Therapeutic Agents in Micellar Nanomedicines

2013 · Lela Vuković, Antonett Madriaga, et al. · Langmuir · 23

Novel histone deacetylase 8 ligands without a zinc chelating group: Exploring an ‘upside-down’ binding pose

2012 · Aditya Sudheer Vaidya, Raghupathi Neelarapu, et al. · Bioorganic & Medicinal Chemistry Letters · 22

Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2

2012 · Aditya Sudheer Vaidya, Bhargava Karumudi, et al. · Bioorganic & Medicinal Chemistry Letters · 14

Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine‐based Histone Deacetylase Inhibitors

2017 · Hazem Abdelkarim, Raghupathi Neelarapu, et al. · ChemMedChem · 12

Photoreactive “Nanorulers” Detect a Novel Conformation of Full Length HDAC3-SMRT Complex in Solution

2013 · Hazem Abdelkarim, Michael Brunsteiner, et al. · ACS Chemical Biology · 11

Abstract 1313: CPI-818: A selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) that inhibits T-cell receptor signaling, promotes Th1 skewing, and achieves objective tumor responses when administered to dogs with T cell lymphomas

2019 · James W. Janc, Craig M. Hill, et al. · Cancer Research · 3

Abstract DDT02-01: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer

2015 · Daniel J. Anderson, Ronan Le Moigne, et al. · Cancer Research · 2

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

2019 · Patrick P. Ng, Mehrdad Mobasher, et al. · Blood

Abstract 1313: CPI-818: A selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) that inhibits T-cell receptor signaling, promotes Th1 skewing, and achieves objective tumor responses when administered to dogs with T cell lymphomas

2019 · James W. Janc, Craig M. Hill, et al. · Experimental and Molecular Therapeutics

Abstract 4541: Utilization of K48 poly-ubiquitin modulation as a biomarker of target engagement for a protein homeostasis inhibitor in the clinic: Preclinical validation with CB-5083, a first-in-class inhibitor of the AAA ATPase p97

2016 · Mary-Kamala MENON, Ferdie SORIANO, et al. · Cancer Research

CB‐5083: A p97 Inhibitor Disrupts Cellular Protein Homeostasis and Shows Potent Anti‐Tumor Effects

2015 · Brajesh Kumar, Julie Rice, et al. · The FASEB Journal

Evaluation of Photoreactive and Phenothiazine-based HDAC Inhibitors

2014 · Antonett P. Madriaga (7989419) · Figshare

Highly Pegylated Sterically Stabilized Micelles in Aqueous Media: Structure, Dynamics, and Storage of Therapeutic Agents

2012 · Lela Vukovic, Fatima A. Khatib, et al. · Biophysical Journal

Works count: 17

Citation count: 893

H-index: 9

I10-index: 9